AVITA Medical (RCEL) 10-K 27 Aug 20 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Jun. 30, 2020	Aug. 20, 2020	Dec. 31, 2019
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Document Annual Report	true
Document Transition Report	false
Entity Registrant Name	Avita Therapeutics, Inc.
Entity Central Index Key	0001762303
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Security Exchange Name	NASDAQ
Trading Symbol	RCEL
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		21,468,494
Entity Public Float			$ 963,450,796

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
ASSETS
Cash	$ 73,639	$ 20,174
Accounts receivable, net	2,076	1,403
BARDA receivables	356	382
R&D tax credits		126
Prepaids and other current assets	990	1,098
Restricted cash	201	200
Inventory	1,125	742
Total current assets	78,387	24,125
Plant and equipment, net	1,363	1,309
Operating lease right-of-use assets	2,347
Intangible assets	364	225
Other long term assets	1	125
Total assets	82,462	25,784
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	4,333	1,916
Accrued wages and fringe benefits	2,816	2,127
Other current liabilities	560	438
Total current liabilities	7,709	4,481
Contract liabilities	435	429
Operating lease liabilities, long term	1,917
Other long term liabilities		42
Total liabilities	10,061	4,952
Contingencies (Note 10)
Shareholders' Equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 21,467,912 and 18,712,996 shares issued and outstanding at June 30, 2020 and 2019, respectively	3	3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at June 30, 2020 and 2019
Additional paid-in capital	259,165	165,473
Accumulated other comprehensive income	8,146	8,184
Accumulated deficit	(194,913)	(152,828)
Total shareholders' equity	72,401	20,832
Total liabilities and shareholders' equity	$ 82,462	$ 25,784

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Jun. 30, 2019
Statement of Financial Position [Abstract]
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	21,467,912	18,712,996
Common stock shares outstanding	21,467,912	18,712,996
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 14,263	$ 5,474	$ 929
Cost of sales	2,973	1,271	546
Gross profit	11,290	4,203	383
BARDA income	3,926	5,921	7,734
Operating Expenses:
Sales and marketing expenses	14,813	12,253	4,875
General and administrative expenses	18,135	13,581	9,403
Research and development expenses	8,461	7,872	6,257
Share-based compensation	16,486	1,946	1,423
Total operating expenses	57,895	35,652	21,958
Operating loss	(42,679)	(25,528)	(13,841)
Interest expense	33	27	21
Other income	686	332	53
Loss before income taxes	(42,026)	(25,223)	(13,809)
Income tax benefit (expense)	(4)	121	1,074
Net loss	$ (42,030)	$ (25,102)	$ (12,735)
Net loss per common share:
Basic	$ (2.07)	$ (1.56)	$ (1.37)
Diluted	$ (2.07)	$ (1.56)	$ (1.37)
Weighted-average common shares:
Basic	20,290,966	16,064,588	9,326,810
Diluted	20,290,966	16,064,588	9,326,810

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance at Jun. 30, 2017	$ 3,929	$ 1	$ 110,861	$ 8,058	$ (114,991)
Beginning balance, shares at Jun. 30, 2017		6,732,198
Net loss	(12,735)				(12,735)
Issuance of common stock under direct placement	22,792	$ 1	22,791
Issuance of common stock under direct placement, shares		6,329,615
Issuance costs associated with direct placement	(1,435)		(1,435)
Share-based compensation	1,423		1,423
Issuance of common stock to director in lieu of directors fees	33		33
Issuance of common stock to director in lieu of directors fees, shares		6,970
Cancelled shares		(295,000)
Translation gain (loss)	25			25	0
Ending Balance at Jun. 30, 2018	14,032	$ 2	133,673	8,083	(127,726)
Ending Balance, shares at Jun. 30, 2018		12,773,783
Net loss	(25,102)				(25,102)
Issuance of common stock under direct placement	32,454	$ 1	32,453
Issuance of common stock under direct placement, shares		5,870,613
Issuance costs associated with direct placement	(2,934)		(2,934)
Share-based compensation	1,946		1,946
Exercise of stock options	335		335
Exercise of stock options, shares		68,600
Translation gain (loss)	101			101
Ending Balance at Jun. 30, 2019	20,832	$ 3	165,473	8,184	(152,828)
Ending Balance, shares at Jun. 30, 2019		18,712,996
Net loss	(42,030)				(42,030)
Issuance of common stock under direct placement	81,702		81,702
Issuance of common stock under direct placement, shares		2,033,898
Issuance costs associated with direct placement	(5,077)		(5,077)
Share-based compensation	16,486		16,486
Exercise of stock options	$ 474		474
Exercise of stock options, shares	99,982	99,982
Vesting of RSU options
Vesting of RSU options, shares		605,183
Issuance of common stock to director in lieu of directors fees	107		107
Issuance of common stock to director in lieu of directors fees, shares		15,853
Translation gain (loss)	(38)			(38)
Beginning balance adjustment related ot the adoption of ASC 842	(55)				(55)
Ending Balance at Jun. 30, 2020	$ 72,401	$ 3	$ 259,165	$ 8,146	$ (194,913)
Ending Balance, shares at Jun. 30, 2020		21,467,912

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Net Loss	$ (42,030)	$ (25,102)	$ (12,735)
Other comprehensive income gain/(loss):
Foreign currency translation gain/(loss)	(38)	101	25
Comprehensive loss	$ (42,068)	$ (25,001)	$ (12,710)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities:
Net loss	$ (42,030)	$ (25,102)	$ (12,735)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	465	269	110
Non-cash lease expense	502
Loss on fixed assset disposal	259	2
Loss on foreign currency transactions	7	397	95
Provision for bad debt expense	43	6	15
Provision for inventory obsolesence	84	89	31
Share-based compensation	16,486	1,946	1,423
Issuance of common stock to directors in lieu of directors fees	107		33
R&D tax credit benefit		(129)	(1,101)
Changes in operating assets and liabilities:
Trade and other receivables	(729)	(1,291)	(27)
BARDA receivables	26	1,522	(1,889)
R&D tax credits	121	1,742	26
Prepaids and other current assets	219	(315)	174
Inventory	(468)	17	(94)
Operating lease liability	(476)
Other long term assets		(4)	(1)
Accounts payable and accrued expenses	2,308	69	280
Accrued wages and fringe benefits	693	737	700
Other current liabilities	(366)	384	5
Contract liabilities	6	429
Other long term liabilities	(4)	(18)	(5)
Net cash used in operations	(22,747)	(19,250)	(12,960)
Cash flows from investing activities:
Cash paid for property and equipment	(590)	(1,021)	(365)
Cash paid for patent filing fees	(257)	(206)
Net cash used in investing activities	(847)	(1,227)	(365)
Cash flow from financing activities:
Proceeds from direct placement of common stock	81,702	32,453	22,791
Issuance cost associated with direct placement	(5,077)	(2,934)	(1,435)
Principal repayment of finance lease	(42)	(62)	(61)
Proceeds from exercise of stock options	474	252
Net cash provided by financing activities	77,057	29,709	21,295
Effect of foreign exchange rate on cash and restricted cash	3	156	102
Net increase in cash and restricted cash	53,466	9,388	8,072
Cash and restricted cash at beginning of year	20,374	10,986	2,914
Cash and restricted cash end of year	73,840	20,374	10,986
Supplemental Disclosure of Cash Flow Information
Interest	42	27	21
Fixed assets in accounts payable	$ 85	$ 15	$ 9

The Company

The Company	12 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ U.S. GAAP Nature of the Business The AVITA group of companies (comprising AVITA Therapeutics, Inc. (“AVITA Therapeutics” or the “Company”) and its subsidiaries, including AVITA Medical Limited (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a commercial-stage regenerative tissue company focused on the treatment of burns, trauma and other acute injuries, including vitiligo. The Company’s lead product is the RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On ™ FDA IDEs In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“ COVID-19 Redomiciliation On June 29, 2020, the Company, a newly formed Delaware corporation, acquired all of the issued share capital of AVITA Medical Limited (“ AVITA Medical ADSs CDIs ADSs NASDAQ As part of the exchange of shares under the Redomiciliation, a reverse split was also simultaneously implemented such that the number of shares of common stock on issue in the Company (as set out in the consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. The Redomiciliation resulted in the domicile of the AVITA Group moving from Australia to the United States of America, with AVITA Therapeutics becoming the ultimate parent company of the AVITA Group. In addition, the existing listing of AVITA Medical ordinary shares on the Australian Securities Exchange (“ ASX As a result of the Redomiciliation, the reporting currency of the AVITA Group has changed from the Australian dollar to the U.S. dollar. In accordance with SEC regulation, SX Rule 320 (e), the impact of the change in the reporting currency was included in a component of other comprehensive income (loss).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. As a result of the redomiciliation described above, the parent company of the AVITA group changed from AVITA Medical to AVITA Therapeutics, Inc. All intercompany transactions and balances have been eliminated on consolidation. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for income taxes and stock-based compensation) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts. Foreign Currency Translation The financial position and results of operations of the Company’s non-U.S. Revenue Recognition Revenues are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. Effective July 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers For the Company’s contracts that have an original duration of one year or less, the Company used the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred. Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized. Income Taxes Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. The Company reviews its uncertain tax positions regularly. An uncertain tax position represents the Company’s expected treatment of a tax position taken in a filed return, or planned to be taken in a future tax return or claim that has not been reflected in measuring income tax expense for financial reporting purposes. The Company recognizes the tax benefit from an uncertain tax position when it is more-likely-than-not Cash Cash consists of cash held at deposit institutions. The Company holds cash denominated in foreign currencies in foreign institutions of approximately $466,000 and $476,000 as of June 30, 2020 and 2019, respectively. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of June 30, 2020, and 2019, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of June 30, 2020, no single customer accounted for more than 10% of total revenues or net accounts receivable. As of June 30, 2019, one customer accounted for approximately 10.5% of total revenues and three customers accounted for more than 10% of net accounts receivable, each representing approximately 14.6%, 10.3% and 10.1 % of total net accounts receivable. As of June 30, 2018, four customers accounted for more than 10% of total revenues, each representing approximately 17%, 14.5%, 12.8% and 10.4% of total revenues. Restricted Cash Pursuant to a contractual agreement with American Express to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $200,000 as of June 30, 2020 and 2019, respectively. Fair Value of Financial Instruments The carrying values of the Company’s financial instruments, consisting of cash, trade receivables, prepaids and other receivables, accounts payable, accrued liabilities and contract liabilities, approximate fair value due to the relative short-term nature of these instruments. Accounts Receivable Accounts receivable are recorded net of customer allowances for doubtful accounts. The Company estimates an allowance for expected credit losses (i.e., the inability of our customers to make required payments). These estimates are based on a combination of past experience and current trends. In estimating the allowance for expected credit losses, consideration is given to the current aging of receivables, a specific review for potential bad debts and an evaluation of historic write-offs. The resulting bad debt expense is included in sales and marketing expenses in the consolidated statement of operations. Receivables are written-off A rollforward of the activity in the Company’s allowance for doubtful account is as follows (in thousands): June 30, 2020 2019 2018 Allowance for doubtful accounts at beginning of the year $ 18 $ 17 $ 68 Bad debt expense 43 6 15 Deductions (43 ) (5 ) (66 ) Allowance for doubtful accounts at end of the year $ 18 $ 18 $ 17 BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA grant is earned and recognized under a cost-plus-fixed-fee fixed-fee The Company has concluded that grants under the BARDA grantt are not within the scope of ASC 606, as they do not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Accounting for Government Grants and Disclosure of Government Assistance, Inventory Inventory is valued at the lower of cost or estimated net realizable value and is reflected in cost of sales. Costs incurred in bringing each product to its present location and condition are accounted for at purchase cost on a first-in, first-out FIFO Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and costs to complete the sale. Leases Effective July 1, 2019, operating leases give rise to operating lease right-of-use Property, Plant and Equipment The Company’s property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed based on the straight-line method over the estimated useful lives of the various asset classes, generally three to seven years. Leasehold improvements are amortized over the shorter of the life of the related asset or the remaining term of the lease. Costs associated with customized internal-use Intangible Assets The Company maintains definite-lived intangible assets related to patents initially measured at cost and amortized over estimated useful lives of approximately 3—20 years. The Company had capitalized patent costs of $483,000 and $225,000 as of June 30, 2020 and 2019, respectively, related to regulatory approval of the RECELL System, and are being amortized over their estimated useful lives. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the estimated, undiscounted future cash flows is less than the carrying amount of the asset, then an impairment is recognized for the amount by which the carrying value of the asset exceeds its estimated fair value. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. There were no impairments of long-lived assets in the years ended June 30, 2020, 2019 and 2018. Sales and Marketing Expenses Sales and marketing expenses consist primarily of compensation and employee benefits of sales and marketing personnel and related sales support teams, marketing events, advertising costs, travel, trade shows and other marketing materials. The Company expenses all selling and marketing costs as incurred. Research and Development Expenses Research and development expenses represent costs incurred to develop the Company’s products. Research and development expenses consist primarily of salaries and other personnel costs, clinical trial costs, regulatory costs and manufacturing costs for non-commercial Stock-Based Compensation The Company records compensation expense for stock options based on the fair market value of the awards on the date of grant. The fair value of stock-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is measured based on the number of shares ultimately expected to vest, estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. For certain awards, the Company estimates the fair value of share options and other equity-based compensation using a Binomial option pricing model on the date of grant. The Binomial model requires multiple subjective inputs, which are discussed further in Note 13 — Share-Based Payment Plans. Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive ordinary shares from option exercises, employee share awards, and other dilutive instruments that have been issued. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be anti-dilutive. The loss per share incorporates the impact of the reverse stock split that was effectuated in conjunction with the redomicilation. In accordance with ASC 260, the impact of the reverse stock split was retrospectively applied for all periods presented. Segment Reporting Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as one segment.

Accounting Standards Update

Accounting Standards Update	12 Months Ended
	Jun. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Update	3. Accounting Standards Update Recently Adopted Effective July 1, 2018, the Company adopted ASU 2014-09 Revenue from Contracts with Customers Effective July 1, 2019, the Company adopted ASU 2016-02, Leases ASC 842 ) right-of-use right-of-use In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows ASC 230 ) Restricted Cash beginning-of-period end-of-period In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation ASC 718 ) Improvements to Employee Share-Based Payment Accounting 2016-09 2016-09 In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses ASC 326 ) Measurement of Credit Losses on Financial Instruments 2016-13 written-off Recent Accounting Pronouncements Not Yet Adopted In August 2018, the FASB Issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use 350-40): 2018-15 In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes 2019-12, Income Taxes 2019-12

Leases

Leases	12 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	4. Leases On July 1, 2019, the Company adopted Accounting Standards Codification No. 842, Leases ASC 842 right-of-use The Company elected the practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs for our leases which existed and expired prior to the adoption date. For existing or expired contracts as of the adoption date, the conclusions made for these items under previous accounting standards (ASC 840) were retained at transition as allowed by the guidance. The Company has also made accounting policy elections, including a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with expected terms of 12 months or less), and an accounting policy to account for lease and certain non-lease At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company has finance leases for equipment and furniture. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to renew the lease. On July 1, 2019, the Company recorded operating lease right-of-use ROU assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate (“ IBR The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease The Company’s agreements may contain variable lease payments. The Company includes variable lease payments that depend on an index or a rate and excludes those which depend on facts or circumstances occurring after the commencement date, other than the passage of time. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the finance lease ROU assets and finance lease liabilities. Some leases require variable payments for common area maintenance, property taxes, parking, insurance, and other variable costs. The variable portion of lease payments is not included in operating lease ROU assets or operating lease liabilities. Variable lease costs are expensed when incurred. The following table sets forth the Company’s operating lease expense which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Year Ended June 30, 2020 Operating lease cost $ 701 Variable lease cost 47 Total lease cost $ 748 Supplemental cash flow information related to operating leases for the year ended June 30, 2020 was as follows (in thousands): Year Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows due to operating leases $ 675 Right-of-use Operating leases — Supplemental balance sheet information, as of June 30, 2020, related to operating leases was as follows (in thousands): June 30, 2020 Reported as: Operating lease right-of-use $ 2,347 Total right-of-use 2,347 Other current liabilities: Operating lease liability, short-term 533 Operating lease liabiltiies, long term 1,917 Total operating lease liabilities $ 2,450 Operating lease weighted average remaining lease term (years) 3.91 Operating lease weighted average discount rate 7.50 % As of June 30, 2020, maturities of the Company’s operating lease liabilities are as follows (in thousands): Years Ending June 30, Operating Leases 2021 $ 695 2022 717 2023 740 2024 588 2025 87 Total lease payments $ 2,827 Less imputed interest 377 Total operating lease liabilities $ 2,450 At June 30, 2020, there were no leases entered into that had not yet commenced. Under legacy lease accounting (“ ASC 840 non-cancellable (in thousands): Years Ending June 30, Operating Leases 2021 $ 530 2022 77 Total operating lease liabilities $ 607

Inventory

Inventory	12 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventory	5. Inventory The composition of inventories is as follows (in thousands): Year Ended June 30, 2020 2019 Raw materials and components $ 947 $ 638 Finished goods 178 104 Total inventory $ 1,125 $ 742 The Company has reduced the carrying value of its inventories to reflect the lower of cost or market value. Charges for estimated excess and obsolescence are recorded in cost of sales in the consolidated statement of operations. Inventory impairments recognized in cost of sales are a result of expired product and were $306,000, $36,000, and $0 for the years ended June 30, 2020, 2019 and 2018, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets The composition of intangible assets is as follows (in thousands): As of June 30, 2020 As of June 30, 2019 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 3 $ 235 $ (101 ) $ 134 $ 151 $ — $ 151 Patent 2 14 74 (9 ) 65 22 — 22 Patent 3 15 125 (9 ) 116 52 — 52 Patent 5 20 26 — 26 — — — Trademarks Indefinite 23 — 23 — — — Total intangible assets $ 483 $ (119 ) $ 364 $ 225 $ — $ 225 During the years ended June 30, 2020 and 2019, the Company did not identify any events or changes in circumstances that indicated the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the years ended June 30, 2020, 2019 and 2018. Amortization expense of intangibles included in the consolidated statements of operations was $119,000, $0 and $0 for the years ended June 30, 2020, 2019 and 2018, respectively. The Company expects the future amortization of amortizable intangible assets held at June 30, 2020 to be (in thousands): Estimated Amortization 2021 $ 100 2022 70 2023 16 2024 15 2025 15 2026 and thereafter 125 Total $ 341

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	7. Property, Plant and Equipment The composition of property, plant and equipment, net is as follows (in thousands): Year Ended June 30, Useful Lives 2020 2019 Computer equipment 3-5 years $ 802 $ 462 Computer software 3 years 369 219 Construction in progress 138 470 Furniture and fixtures 7 years 425 399 Laboratory equipment 5 years 194 143 Leasehold improvements Lesser of life 216 155 RECELL moulds 5 years 100 128 Less: accumulated amortization and depreciation (881 ) (667 ) Total property, plant and equipment, net $ 1,363 $ 1,309 Depreciation expense related to plant and equipment was $346,000, $269,000 and $110,000 for the years ended June 30, 2020, 2019 and 2018, respectively.

Prepaids and Other Current Asse

Prepaids and Other Current Assets	12 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaids and Other Current Assets	8. Prepaids and Other Current Assets Prepaids and Other current assets consisted of the following (in thousands): Year Ended June 30, 2020 2019 Prepaid expenses $ 792 $ 933 Lease deposits 123 40 Other receivables 75 125 Total prepaids and other current assets $ 990 $ 1,098 Prepaid expenses primarily consist of prepaid benefits and insurance.

Reporting Segment and Geographi

Reporting Segment and Geographic Information	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	9. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of June 30, 2020 and 2019 with an insignificant amount located in Australia and the United Kingdom. Revenue by region for the years ended June 30, 2020, 2019 and 2018 were as follows (in thousands): Year Ended June 30, 2020 2019 2018 Revenue: United States $ 13,800 $ 4,404 $ — Foreign: Australia 292 806 550 United Kingdom 171 264 379 Total $ 14,263 $ 5,474 $ 929

Contingencies

Contingencies	12 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	10. Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of June 30, 2020, the Company does not have any outstanding or threatened litigation that would have a material impact to the financial statements.

Common and Preferred Stock

Common and Preferred Stock	12 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Common and Preferred Stock	11. Common and Preferred Stock On June 29, 2020, a statutory scheme of arrangement under Australian law to effect a redomiciliation of the AVITA Group from Australia to the United States of America was implemented (“the Scheme”). The Scheme was approved by shareholders on June 15, 2020 and approved by the Federal Court of Australia on June 22, 2020. Pursuant to the Scheme, all ordinary shares in AVITA Medical, the former parent company of the AVITA Group, were exchanged for shares of common stock in AVITA Therapeutics. As a result, AVITA Therapeutics became the sole shareholder of AVITA Medical and the new parent company of the AVITA Group. In conjunction with the Scheme, an implicit reverse split on a 1 for 100 basis was implemented whereby shareholders of AVITA Medical received one share of common stock in AVITA Therapeutics for every 100 shares held in AVITA Medical. Under the Scheme, eligible shareholders in AVITA Medical Limited received consideration in the form of: • five CDIs • one share of common stock in the Company for every 5 ADS s The Company’s CDIs are quoted on the ASX under AVITA Medical’s existing ASX ticker code, “AVH”. The Company’s shares of common stock are quoted on NASDAQ under AVITA Medical’s existing NASDAQ ticker code, “RCEL”. One share of common stock on NASDAQ is equivalent to five CDIs on the ASX. As a result of the ‘implicit consolidation’ that occurred under the Scheme, the number of shares of common stock on issue in the Company (as set out in the consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. All common share amounts included in these financial statements have been retroactively reduced by a factor of one hundred and all per share amounts have been increased by a factor or one hundred, with the exception of the Company’s common stock par value. The Company is authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of June 30, 2020, and 2019, 21,467,912 and 18,712,996 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. During the year ended June 30, 2020, the AVITA Group raised additional capital via a private placement in the amount of $81.7 million (through our former parent company, AVITA Medical). The Company sold 2,033,898 ordinary shares at an issue price of $40.17 per share for total net proceeds of $76.6 million, after deducting commission and offering expenses. An aggregate 15,853 ordinary shares were issued to the directors of the Company in lieu of director fees during the year ended June 30, 2020 under the Director Share Plan that was approved in December 2017. During the year ended June 30, 2019, the AVITA Group completed a series of equity transactions (through our former parent company, AVITA Medical). The second tranche of the June 2018 Placement (defined below) closed on July 27, 2018, raising an aggregate of $2.4 million through the issuance of the equivalent of 650,000 shares at $3.70 per share. During December 2018, AVITA Medical entered into a placement agreement to raise $28.8 million over two tranches. AVITA Medical completed the first tranche on December 10, 2018 and issued the equivalent of 3,100,471 shares at a price of $5.76 per share raising gross proceeds of $17.9 million. The settlement of the second tranche for $10.9 million was approved by the shareholders at an extraordinary meeting held during January 2019. The second tranche closed on January 18, 2019 and raised gross proceeds of $10.9 million through the sale of the equivalent of 1,899,530 shares at the same price as the first tranche, being $5.76 per share. In addition, on January 10, 2019, AVITA Medical completed a Share Purchase Plan under which AVITA Medical offered to existing eligible shareholders the opportunity to purchase shares at a purchase price equivalent to $5.74 per share. As part of the Share Purchase Plan AVITA Medical received gross proceeds of $1.3 million for the issuance of the equivalent of 220,612 shares. During the year ended June 30, 2018, the AVITA Group completed a series of equity transactions (through its former parent company, AVITA Medical). During October 2017, AVITA Medical announced that it was undertaking a capital raising in aggregate to raise $13.2 million. The capital raise was split over two tranches; the first being a private placement and the second a rights offering to existing shareholders. On October 17, 2017, AVITA Medical completed the private placement of the equivalent of 1,009,830 shares at a price of $3.53 per share raising gross proceeds of $3.6 million. On November 2, 2017, AVITA Medical completed the rights offering resulting in a total issue of the equivalent of 2,765,029 shares to raise a gross total of $9.6 million. During June 2018, AVITA Medical announced an institutional placement to raise an aggregate of $12.1 million over two tranches (“ June 2018 Placement During December 2017, the board of directors approved the 2016 Director Share Plan which previously allowed directors to convert their compensation into ordinary shares. A total of the equivalent of 6,970 shares were issued under the Director Share Plan. Future issuances are no longer authorized under the Director Share Plan.

Revenue

Revenue	12 Months Ended
	Jun. 30, 2020
Revenue, Performance Obligation [Abstract]
Revenue	12. Revenue The Company adopted ASC Topic 606 – Revenue from Contracts with Customers To determine revenue recognition for arrangements that are within the scope of Topic 606, the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as performance obligation(s) are satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. Revenues The Company’s revenue consists of sale of the RECELL System to hospitals or other treatment centers (“ customers Performance Obligations The Company’s contracts typically have a single performance obligation to deliver the product to the customer. The transaction price is stated within the contract and is therefore fixed consideration. The transaction price does not include the sales tax that are imposed by governmental authority. We identified the hospital or treatment center as the customer in Step 1 of the model above and have determined a contract exists with those customers in Step 1. As these contracts typically have a single performance obligation (i.e. product delivery), no allocation of the transaction price is required in Step 4 of the model. Control product is transferred to the customer at a point in time. Specifically, we determined the customer obtains control of the product at point in time at which the goods are either shipped or delivered to our customers’ facilities, depending on the terms of the contract. Variable Consideration Revenue from the sale of goods is recognized net of volume discounts. The Company uses the expected value method when estimating variable consideration. Revenue is only recognized to the extent that it is probable that a significant reversal will not occur. The Company evaluates its contracts with customers for forms of variable consideration, which may require an adjustment to the transaction price based on their estimated impact. Revenues from product sales are recorded at the sales price, net of volume discounts. Volume Discounts 12-month customer-by-customer Contract Assets and Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of the period ended June 30, 2020 and 2019, the Company does not have any contract assets. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $435,000 and $429,000 of contract liabilities as of June 30, 2020 and 2019, respectively. For the years ended June 30, 2020 and 2019, revenue recognized from amounts included in the beginning balance of contract liabilities was not significant. Cost to Obtain and Fulfill a Contract Contract fulfillment costs include commissions and shipping expenses. The Company has opted to immediately expense the incremental cost of obtaining a contract when the underlying related asset would have been amortized over one year or less. The Company generally does not incur costs to obtain new contracts. Remaining Performance Obligations Since the Company’s adoption of ASC 606 on July 1, 2018, revenues from remaining performance obligations are now calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $435,000 and $429,000 as of June 30, 2020 and 2019, respectively. The Company expects to recognize these amounts upon receiving Japanese Pharmaceuticals and Medical Device Act approval of the RECELL System in Japan.

Share-Based Payment Plans

Share-Based Payment Plans	12 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Payment Plans	13. Share-Based Payment Plans Overview of Employee Share-Based Compensation Plans In November 2014, our former parent company, AVITA Medical, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the “ 2016 Plans The 2016 Plans were governed by the Compensation Committee. Subject to Board approval where required by applicable law, the Compensation Committee previously had the authority, in its sole discretion, to grant options under the 2016 Plans, to interpret the provisions of the 2016 Plans, and to prescribe, amend, and rescind rules and regulations relating to the 2016 Plans or any issue or grant thereunder as it may deem necessary or advisable, subject to any other approval if required by applicable law. All decisions made by the Compensation Committee pursuant to the provisions of the 2016 Plans were final, conclusive and binding on all persons. The number of awards issued, the exercise price and the vesting schedule under the 2016 Plans were determined by the Compensation Committee, in accordance with the provisions of the 2016 Plans. Options granted under the 2016 Plans have an exercise price equal to the share price at the date of grant, or such other exercise price that the Compensatio n The following table summarizes information about the Company’s stock-based award plans as of June 30, 2020: Outstanding Outstanding Shares Available for 2016 Plan 1,260,524 0 0 RSU Awards 0 339,359 0 Share-Based Payment Expenses Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The Company uses the Binomial option valuation model to estimate the grant date fair value of employee stock options. During the years ended June 30, 2020, 2019 and 2018, the Company recorded stock-based compensation expense of $16.5 million, $1.9 million, and $1.4 million. No income tax benefit was recognized in the consolidated statement of comprehensive loss for share-based payment arrangements for June 30, 2020, 2019 and 2018. A summary of stock option activity under the employees share option plan Service Performance Total Stock Service Weighted- (in years) Aggregate Outstanding at June 30, 2019 817,077 319,717 1,136,794 $ 8.83 8.02 $ 24,679,478 Granted 192,133 67,500 259,633 38.16 Exercised (70,282 ) (29,700 ) (99,982 ) 6.37 Expired (9,270 ) — (9,270 ) 29.45 Forfeited (25,305 ) (1,346 ) (26,651 ) 18.14 Outstanding at June 30, 2020 904,353 356,171 1,260,524 14.72 8.42 22,185,034 Exercisable at June 30, 2020 279,776 221,923 501,699 $ 10.25 8.10 $ 10,520,968 The weighted-average grant-date fair value of options granted during the years 2020, 2019, and 2018 was $26.56, $6.67, and $5.11, respectively. The total intrinsic value of options exercised during the years ended June 30, 2020, 2019 and 2018 was $3.1 million, $1.7 million, and $0, respectively. Intrinsic value is measured using the fair market value at the date of exercise for options exercised, or at June 30 for outstanding options, less the applicable exercise price. Cash received from the exercise of options was approximately $474,000 and $252,000 and $0 for the year ended June 30, 2020, 2019 and 2018, respectively. As of June 30, 2020, there was approximately $5.8 million of total unrecognized compensation cost related to stock options to be recognized over a weighted average period of 1.41 years. Option Pricing Model The fair value of each stock option is estimated on the date of grant using the Binomial valuation model. Expected volatilities are based on historical volatility of the Company’s shares over multiple trading periods, to estimate the future volatility of the Company’s shares over the contractual term of 10 years. The expected term of options granted is derived from the output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the Reserve Bank of Australia’s government bonds, not the U.S. Treasury yield curve in effect at the time of grant. As the Company has never declared dividends, no dividend yield is used in the calculation. Actual value realized, if any, is dependent on the future performance of the Company’s shares and overall stock market conditions. There is no assurance the value realized by an optionee will be at or near the value estimated by the Binomial model. Included in the following table is a summary of the grant-date fair value of stock options granted and the related assumptions used in the Binomial models for stock options granted in fiscal 2020, 2019, and 2018. Year Ended June 30, 2020 2019 2018 Expected volatility 75% - 90% 90% 90% Weighted-average volatility 88% 90% 90% Expected dividends 0% 0% 0% Expected term (in years) 10.0 10.0 1.5 - 10.0 Risk-free interest rate 0.68% - 2.65% 1.50% - 2.65% 1.50% Restricted Stock Units Restricted stock units (RSUs) are granted to executives as part of their long-term incentive compensation. RSU awards are approved by the Compensation Committee as determined necessary. The RSU awards have a contractual term of 10 years and vest in accordance with the tenure or performance conditions as determined by the Compensation Committee. The grant date fair value is determined based on the price of the Company stock on the ASX on the date of grant. RSUs primarily consist of awards to the CEO and other executives. The terms of the awards are described below: CEO RSUs On November 30, 2017, 500,000 RSUs were issued to the CEO with the following vesting terms: a) Tenure – 166,667 shares with a vesting period of three-year s commencing on June 1, 2017. b) Company Share Price – 166,667 shares to vest in three equal tranches subject to the Volume Weighted Average Price (VWAP) of Company share price (as at close of trade on the ASX on relevant date) achieving multiples of 2x, 3x and 4x the Company’s share price at the time of shareholder approval; and c) Milestone performance – 166,666 shares to vest in two equal tranches upon satisfaction of the following milestones: 1. FDA PMA approval of RECELL for burns 2. Initial BARDA procurement under CLIN 2 of the BARDA Grant On November 2019, 395,542 RSUs were issued to the CEO with the following vesting terms: a) Tenure – 142,520 shares with a vesting period of three-year s commencing on June 1, 2020. b) Milestone performance – 253,033 RSUs will vest upon satisfaction of the following milestones: a. First patient visit for treatment in an FDA approved U.S. soft tissue and trauma trial by the Company prior to March 3, 2020. b. First patient visit for treatment in an FDA approved U.S pediatric trial by the Company prior to June 30, 2020, c. First patient visit for treatment in an FDA approved U.S pilot vitiligo trial by the Company prior to September 30, 2020. d. FDA application submission for approval of the next generation RECELL device prior to June 30, 2021. e. FDA approval of the next generation RECELL device prior to June 30, 2022. Other Executive Grants During November 2019, 49,000 RSUs were to executives. A summary of the status of the Company’s unvested shares as of June 30, 2020, and changes during the year ended June 30, 2020, is presented below: Unvested Shares Service Performance Total Weighted Unvested RSUs outstanding at June 30, 2019 166,667 333,333 500,000 $ 4.48 Granted 146,521 298,022 444,543 39.12 Vested (218,175 ) (387,009 ) (605,184 ) 15.22 Forfeited — — — — Unvested RSUs outstanding at June 30, 2020 95,013 244,346 339,359 $ 30.70 The weighted-average grant-date fair value of the RSUs granted during 2020, 2019 and 2018 was $39.12, $0 and $4.48 per unit, respectively. The total fair value of shares vested during the years ended June 30, 2020, 2019 and 2018 was $9.2 million, $0, and $0, respectively. As of June 30, 2020, there was $6.6 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the RSU award agreements. This amount includes $1.9 million for performance share awards that have been determined to be not probable. The associated expense will be recognized once the performance conditions has been determined to be probable. The remaining unrecognized expense of $4.7 million is expected to be recognized over a weighted average period of 0.69 years.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes Geographic sources of income (loss) from continuing operations before income taxes are as follows: Year Ended Year Ended Year Ended (amounts in thousands) June 30, June 30, June 30, United States $ (20,793 ) $ (19,899 ) $ (5,382 ) Foreign (21,233 ) (5,324 ) (8,427 ) Income (loss) from continuing operations before income taxes $ (42,026 ) $ (25,223 ) $ (13,809 ) The income tax benefit (expense) as shown in the accompanying consolidated statements of operations includes the following: Year Ended Year Ended Year Ended (amounts in thousands) June 30, June 30, June 30, Current: Federal $ — $ — $ — State 4 — — Foreign — (121 ) (1,074 ) 4 (121 ) (1,074 ) Deferred: Federal — — — State — — — Foreign — — — — — — Total Income Tax Expense (Benefit) $ 4 $ (121 ) $ (1,074 ) The provision for income taxes differs from the tax computed using the statutory United States federal income tax rate of 21%, 21% and 28% for June 30, 2020, 2019 and 2018 as a result of the following items: (amounts in thousands) Year Ended Year Ended Year Ended Tax expense (benefit) at U.S. statutory rate $ (8,827 ) $ (5,297 ) $ (3,805 ) State income taxes 4 — — Foreign rate differential (1,389 ) (299 ) 120 Tax Credits — (121 ) (1,074 ) Share-based compensation (3,794 ) 535 391 Permanent differences 669 84 796 Change in tax rate — — 2,824 Net change in valuation allowance 13,341 4,977 (326 ) Income tax expense (benefit) $ 4 $ (121 ) $ (1,074 ) A summary of deferred income tax assets is as follows (in thousands): Year Ended June 30, 2020 Year Ended June 30, 2019 Deferred tax liabilities ROU Asset $ (608 ) $ — Total deferred tax liabilities $ (608 ) $ — Deferred tax assets Property, plant and equipment $ 17 $ 7 Accrued expenses 564 15 Intangible assets 255 563 Stock based compensation 2,996 — Lease liability 634 — Net operating loss carryforward 37,756 25,358 Other 285 1 Total deferred tax assets $ 42,507 $ 25,944 Less valuation allowance (41,899 ) (25,944 ) Net deferred tax assets $ 608 $ — Net deferred tax assets / (liabilities) $ — $ — At June 30, 2020, the Company and its subsidiaries had net operating loss carryforwards for federal, state, United Kingdom, and Australia income tax purposes of $88.5 million, $57.5 million, $29.8 million, and $34.1 million respectively. The net operating loss carryforwards may be subject to limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions of the Internal Revenue Code and similar state and foreign provisions. Of these carryforwards, $21.7 million will expire, if not utilized, in various years through 2038. The remaining carryforwards have no expiration. In assessing the recoverability of its deferred tax assets, the Company considers whether it is more likely than not that its deferred assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. The Company considers all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Based upon the weight of available evidence including the uncertainty regarding the Company’s ability to utilize certain net operating losses and tax credits in the future, the Company has established a valuation allowance against its net deferred tax assets of $41.9 million and $25.9 million as of June 30, 2020 and 2019, respectively. The deferred tax assets are primarily net operating loss carryforwards for which management has determined it is more likely than not that the deferred tax assets will not be realized. The Company recognizes the tax benefit from an uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements related to a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. The Company has not identified any uncertain tax positions as of June 30, 2020 or June 30, 2019. The Company files income tax returns in the U.S. federal, California and certain other state and foreign jurisdictions. The Company remains subject to income tax examinations for its U.S. federal and state certain other U .S. state and local income taxes generally for the fiscal years ended June 30, 2016 through June 30, 2019 . The Tax Cuts and Jobs Act (“the Tax Act”) was enacted on December 22, 2017 and reduced U.S. corporate income tax rates to 21% as of January 1, 2018. The rate change became effective during tax year June 30, 2018, resulting in a blended statutory tax rate of 28% and a decrease in the Company’s deferred tax assets and the associated valuation allowance in tax year June 30, 2018. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“ CARES Ac

Loss Per Share

Loss Per Share	12 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Loss Per Share	15. Loss per Share The following is a reconciliation of the basic and diluted loss per share computations: Year Ended June 30, 2020 2019 2018 (in thousands) Net Loss $ 42,030 $ 25,102 $ 12,735 Weighted-average common shares—outstanding, basic 20,291 16,065 9,327 Weighted-average common shares—outstanding, diluted 20,291 16,065 9,327 Net loss per common share, basic $ 2.07 $ 1.56 $ 1.37 Net loss per common share, diluted $ 2.07 $ 1.56 $ 1.37 The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. For the purposes of the calculation of diluted net loss per share options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the years ended June 30, 2020, 2019 and 2019, diluted net loss per common share is the same as the basic net loss per share for those years.

Retirement Plans

Retirement Plans	12 Months Ended
	Jun. 30, 2020
Retirement Benefits [Abstract]
Retirement Plans	16. Retirement Plans The Company offers a 401(k)-retirement savings plan (the “ 401(k) Plan pre-tax

Deed of Cross Guarantee

Deed of Cross Guarantee	12 Months Ended
	Jun. 30, 2020
Guarantees [Abstract]
Deed of Cross Guarantee	17. Deed of Cross Guarantee The Company (as the parent entity of the AVITA Group) is party to a deed of cross guarantee dated June 29, 2020 (“ Deed • AVITA Medical Ltd (ACN 058 466 523) (“ AVITA Medical • C3 Operations Pty Ltd (ACN 090 161 505); • Visiomed Group Pty Ltd (ACN 003 010 580); and • Infamed Pty Limited (ACN 084 800 653), (together, the “ Australian Subsidiaries The Company and the Australian Subsidiaries were the only parties to the Deed at June 30, 2020 and comprise the “closed group” for the purposes of the Deed (and also the “extended closed group”). No parties have been added to or removed from the Deed, or are subject to a notice of disposal, since June 29, 2020. Since June 30, 2020, there has been no change in ownership in any of the Australian Subsidiaries. By entering into the deed, the Company and the Australian Subsidiaries have guaranteed the debts of each other. Relief under ASIC Corporations (Wholly-owned Companies) Instrument 2016/785 By entering into the Deed, the Australian Subsidiaries, except for Avita Medical, have been relieved from the requirement to prepare a financial report and directors’ report for the financial year ended June 30, 2020 under ASIC Corporations (Wholly-owned Companies) Instrument 2016/785 Relief under ASIC Instrument 20-0431 Avita Medical, being the former parent entity of the Avita Group, is unable to rely on the relief provided under ASIC Corporations (Wholly-owned Companies) Instrument 2016/785 Corporations Act 2001 ASIC 20-0431 Instrument In order to comply with the conditions to the relief provided in the Instrument, the Australian Subsidiaries (including Avita Medical) entered into the Deed with the Company on June 29, 2020. Consolidated financial information of parties to the Deed The financial statements below are additional disclosure items specifically required by ASIC and represent the consolidated financial statements of the entities that are party to the Deed only (being the ‘closed group’ and also the ‘extended closed group’ under the Deed). (in thousands) Year Ended June 30, Revenues $ 292 Cost of sales 335 Gross profit (43 ) Operating Expenses: Sales and marketing expenses 488 General and administrative expenses 5,013 Research and development expenses 103 Share-based compensation 16,486 Total operating expenses 22,090 Operating loss (22,133 ) Interest expense 20 Other income 2 Loss before income taxes (22,151 ) Income tax benefit (expense) — Net loss $ (22,151 ) June 30, ASSETS Cash $ 403 Accounts receivable, net 17 R&D tax credits — Prepaids and other current assets 414 Inventory 23 Total current assets 857 Plant and equipment, net 1 Intangibles 364 Total assets $ 1,222 LIABILITIES AND STOCKHOLDERS’ EQUITY Accounts payable and accrued liabilities $ 1,946 Accrued wages and fringe benefits 70 Other current liabilities — Total liabilities $ 2,016 Contributed Equity 232,747 Reserves 31,345 Accumulated deficit (264,886 ) Total stockholders’ equity (deficit) (794 ) Total liabilities and stockholders’ equity (deficit) $ 1,222

Quarterly Results (Unaudited)

Quarterly Results (Unaudited)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (Unaudited)	18. Quarterly Results (Unaudited) (in thousands, except per share data) Year Ended June 30, September 30, December 31, March 31, June 30, 2020 Revenues $ 3,250 $ 3,259 $ 3,877 $ 3,877 Cost of sales 619 846 634 874 Gross profit 2,631 2,413 3,243 3,003 BARDA income 2,051 386 1,008 481 Operating Expenses: Sales and marketing expenses 2,962 3,738 4,162 3,951 General and administrative expenses 3,071 4,558 4,145 6,361 Research and development expenses 1,635 2,192 2,302 2,332 Share-based compensation 672 2,903 9,048 3,863 Total operating expenses 8,340 13,391 19,657 16,507 Operating loss (3,658 ) (10,592 ) (15,406 ) (13,023 ) Interest expense 11 9 5 8 Other income/(expense) 103 99 363 121 Loss before income taxes (3,566 ) (10,502 ) (15,048 ) (12,910 ) Income tax benefit (expense) — — — (4 ) Net loss $ (3,566 ) $ (10,502 ) $ (15,048 ) $ (12,914 ) Net loss per common share: Basic $ (0.19 ) $ (0.53 ) $ (0.71 ) $ (0.60 ) Diluted $ (0.19 ) $ (0.53 ) $ (0.71 ) $ (0.60 ) Weighted-average common shares: Basic 18,719,857 19,877,676 21,215,246 21,372,892 Diluted 18,719,857 19,877,676 21,215,246 21,372,892 (in thousands, except per share data) Year Ended June 30, September 30, December 31, March 31, June 30, 2019 Revenues $ 269 $ 1,040 $ 1,710 $ 2,455 Cost of sales 232 242 292 505 Gross profit 37 798 1,418 1,950 BARDA income 1,862 1,753 1,238 1,068 Operating Expenses: Sales and marketing expenses 2,163 2,840 3,309 3,941 General and administrative expenses 2,605 3,399 3,650 3,927 Research and development expenses 1,972 2,019 1,809 2,072 Share-based compensation 217 593 567 569 Total operating expenses 6,957 8,851 9,335 10,509 Operating loss (5,058 ) (6,300 ) (6,679 ) (7,491 ) Interest expense 6 5 5 11 Other income/(expense) 37 $ 39 $ 502 $ (246 ) Loss before income taxes (5,027 ) (6,266 ) (6,182 ) (7,748 ) Income tax benefit (expense) (7 ) — — 128 Net loss $ (5,034 ) $ (6,266 ) $ (6,182 ) $ (7,620 ) Net loss per common share: Basic $ (0.38 ) $ (0.44 ) $ (0.34 ) $ (0.41 ) Diluted $ (0.38 ) $ (0.44 ) $ (0.34 ) $ (0.41 ) Weighted-average common shares: Basic 13,240,087 14,165,200 18,263,535 18,665,604 Diluted 13,240,087 14,165,200 18,263,535 18,665,604

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events The Company has considered all events occurring subsequent to June 30, 2020 and has concluded that all significant events have been disclosed in the financial statements and accompanying notes. On July 7, 2020, the Company had a change in Auditors from Grant Thornton Audit Pty Ltd a subsidiary of Grant Thornton Australia Ltd to Grant Thornton LLP, the U.S. member firm of Grant Thornton Internation Ltd. Change in auditors was a result of the redomiciliation of the Company and the SEC filing requirement that resulted upon the redomiciliation. We continue to manage the risk to our business posed by the global COVID-19 stay-at-home The COVID-19 COVID-19 COVID-19

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. As a result of the redomiciliation described above, the parent company of the AVITA group changed from AVITA Medical to AVITA Therapeutics, Inc. All intercompany transactions and balances have been eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for income taxes and stock-based compensation) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.
Foreign Currency Translation	Foreign Currency Translation The financial position and results of operations of the Company’s non-U.S.
Revenue Recognition	Revenue Recognition Revenues are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. Effective July 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers For the Company’s contracts that have an original duration of one year or less, the Company used the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred.
Cost of Sales	Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized.
Income Taxes	Income Taxes Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. The Company reviews its uncertain tax positions regularly. An uncertain tax position represents the Company’s expected treatment of a tax position taken in a filed return, or planned to be taken in a future tax return or claim that has not been reflected in measuring income tax expense for financial reporting purposes. The Company recognizes the tax benefit from an uncertain tax position when it is more-likely-than-not
Cash	Cash Cash consists of cash held at deposit institutions. The Company holds cash denominated in foreign currencies in foreign institutions of approximately $466,000 and $476,000 as of June 30, 2020 and 2019, respectively.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of June 30, 2020, and 2019, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of June 30, 2020, no single customer accounted for more than 10% of total revenues or net accounts receivable. As of June 30, 2019, one customer accounted for approximately 10.5% of total revenues and three customers accounted for more than 10% of net accounts receivable, each representing approximately 14.6%, 10.3% and 10.1 % of total net accounts receivable. As of June 30, 2018, four customers accounted for more than 10% of total revenues, each representing approximately 17%, 14.5%, 12.8% and 10.4% of total revenues.
Restricted Cash	Restricted Cash Pursuant to a contractual agreement with American Express to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $200,000 as of June 30, 2020 and 2019, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of the Company’s financial instruments, consisting of cash, trade receivables, prepaids and other receivables, accounts payable, accrued liabilities and contract liabilities, approximate fair value due to the relative short-term nature of these instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded net of customer allowances for doubtful accounts. The Company estimates an allowance for expected credit losses (i.e., the inability of our customers to make required payments). These estimates are based on a combination of past experience and current trends. In estimating the allowance for expected credit losses, consideration is given to the current aging of receivables, a specific review for potential bad debts and an evaluation of historic write-offs. The resulting bad debt expense is included in sales and marketing expenses in the consolidated statement of operations. Receivables are written-off A rollforward of the activity in the Company’s allowance for doubtful account is as follows (in thousands): June 30, 2020 2019 2018 Allowance for doubtful accounts at beginning of the year $ 18 $ 17 $ 68 Bad debt expense 43 6 15 Deductions (43 ) (5 ) (66 ) Allowance for doubtful accounts at end of the year $ 18 $ 18 $ 17
BARDA Income and Receivables	BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA grant is earned and recognized under a cost-plus-fixed-fee fixed-fee The Company has concluded that grants under the BARDA grantt are not within the scope of ASC 606, as they do not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Accounting for Government Grants and Disclosure of Government Assistance,
Inventory	Inventory Inventory is valued at the lower of cost or estimated net realizable value and is reflected in cost of sales. Costs incurred in bringing each product to its present location and condition are accounted for at purchase cost on a first-in, first-out FIFO Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and costs to complete the sale.
Leases	Leases Effective July 1, 2019, operating leases give rise to operating lease right-of-use
Property, Plant and Equipment	Property, Plant and Equipment The Company’s property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed based on the straight-line method over the estimated useful lives of the various asset classes, generally three to seven years. Leasehold improvements are amortized over the shorter of the life of the related asset or the remaining term of the lease. Costs associated with customized internal-use
Intangible Assets	Intangible Assets The Company maintains definite-lived intangible assets related to patents initially measured at cost and amortized over estimated useful lives of approximately 3—20 years. The Company had capitalized patent costs of $483,000 and $225,000 as of June 30, 2020 and 2019, respectively, related to regulatory approval of the RECELL System, and are being amortized over their estimated useful lives.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the estimated, undiscounted future cash flows is less than the carrying amount of the asset, then an impairment is recognized for the amount by which the carrying value of the asset exceeds its estimated fair value. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss. There were no impairments of long-lived assets in the years ended June 30, 2020, 2019 and 2018.
Sales and Marketing Expenses	Sales and Marketing Expenses Sales and marketing expenses consist primarily of compensation and employee benefits of sales and marketing personnel and related sales support teams, marketing events, advertising costs, travel, trade shows and other marketing materials. The Company expenses all selling and marketing costs as incurred.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred to develop the Company’s products. Research and development expenses consist primarily of salaries and other personnel costs, clinical trial costs, regulatory costs and manufacturing costs for non-commercial
Stock-Based Compensation	Stock-Based Compensation The Company records compensation expense for stock options based on the fair market value of the awards on the date of grant. The fair value of stock-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is measured based on the number of shares ultimately expected to vest, estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. For certain awards, the Company estimates the fair value of share options and other equity-based compensation using a Binomial option pricing model on the date of grant. The Binomial model requires multiple subjective inputs, which are discussed further in Note 13 — Share-Based Payment Plans.
Loss per Share	Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive ordinary shares from option exercises, employee share awards, and other dilutive instruments that have been issued. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be anti-dilutive. The loss per share incorporates the impact of the reverse stock split that was effectuated in conjunction with the redomicilation. In accordance with ASC 260, the impact of the reverse stock split was retrospectively applied for all periods presented.
Segment Reporting	Segment Reporting Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as one segment.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary Of Allowance For Doubtful Account	A rollforward of the activity in the Company’s allowance for doubtful account is as follows (in thousands): June 30, 2020 2019 2018 Allowance for doubtful accounts at beginning of the year $ 18 $ 17 $ 68 Bad debt expense 43 6 15 Deductions (43 ) (5 ) (66 ) Allowance for doubtful accounts at end of the year $ 18 $ 18 $ 17

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Summary Of Lease Cost	The following table sets forth the Company’s operating lease expense which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Year Ended June 30, 2020 Operating lease cost $ 701 Variable lease cost 47 Total lease cost $ 748
Summary Of Supplemental Cash Flow Information Related To Operating Leases	Supplemental cash flow information related to operating leases for the year ended June 30, 2020 was as follows (in thousands): Year Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows due to operating leases $ 675 Right-of-use Operating leases —
Summary Of Supplemental Balance Sheet Information Related To Operating Leases	Supplemental balance sheet information, as of June 30, 2020, related to operating leases was as follows (in thousands): June 30, 2020 Reported as: Operating lease right-of-use $ 2,347 Total right-of-use 2,347 Other current liabilities: Operating lease liability, short-term 533 Operating lease liabiltiies, long term 1,917 Total operating lease liabilities $ 2,450 Operating lease weighted average remaining lease term (years) 3.91 Operating lease weighted average discount rate 7.50 %
Summary Of Maturities Of The Company's Operating Lease Liabilities	As of June 30, 2020, maturities of the Company’s operating lease liabilities are as follows (in thousands): Years Ending June 30, Operating Leases 2021 $ 695 2022 717 2023 740 2024 588 2025 87 Total lease payments $ 2,827 Less imputed interest 377 Total operating lease liabilities $ 2,450
Summary Of Future Minimum Lease Payments Under Non-Cancellable Leases	Under legacy lease accounting (“ ASC 840 non-cancellable (in thousands): Years Ending June 30, Operating Leases 2021 $ 530 2022 77 Total operating lease liabilities $ 607

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Summary Of Composition Of Inventories	The composition of inventories is as follows (in thousands): Year Ended June 30, 2020 2019 Raw materials and components $ 947 $ 638 Finished goods 178 104 Total inventory $ 1,125 $ 742

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary Of Composition Of Intangible Assets	The composition of intangible assets is as follows (in thousands): As of June 30, 2020 As of June 30, 2019 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 3 $ 235 $ (101 ) $ 134 $ 151 $ — $ 151 Patent 2 14 74 (9 ) 65 22 — 22 Patent 3 15 125 (9 ) 116 52 — 52 Patent 5 20 26 — 26 — — — Trademarks Indefinite 23 — 23 — — — Total intangible assets $ 483 $ (119 ) $ 364 $ 225 $ — $ 225
Summary Of Future Amortization Of Amortizable Intangible Assets Held	The Company expects the future amortization of amortizable intangible assets held at June 30, 2020 to be (in thousands): Estimated Amortization 2021 $ 100 2022 70 2023 16 2024 15 2025 15 2026 and thereafter 125 Total $ 341

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Summary Of Composition Of Property, Plant And Equipment	The composition of property, plant and equipment, net is as follows (in thousands): Year Ended June 30, Useful Lives 2020 2019 Computer equipment 3-5 years $ 802 $ 462 Computer software 3 years 369 219 Construction in progress 138 470 Furniture and fixtures 7 years 425 399 Laboratory equipment 5 years 194 143 Leasehold improvements Lesser of life 216 155 RECELL moulds 5 years 100 128 Less: accumulated amortization and depreciation (881 ) (667 ) Total property, plant and equipment, net $ 1,363 $ 1,309

Prepaids and Other Current As_2

Prepaids and Other Current Assets (Tables)	12 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaids And Other Current Assets	Prepaids and Other current assets consisted of the following (in thousands): Year Ended June 30, 2020 2019 Prepaid expenses $ 792 $ 933 Lease deposits 123 40 Other receivables 75 125 Total prepaids and other current assets $ 990 $ 1,098

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule Of Revenue By Region	Revenue by region for the years ended June 30, 2020, 2019 and 2018 were as follows (in thousands): Year Ended June 30, 2020 2019 2018 Revenue: United States $ 13,800 $ 4,404 $ — Foreign: Australia 292 806 550 United Kingdom 171 264 379 Total $ 14,263 $ 5,474 $ 929

Share-Based Payment Plans (Tabl

Share-Based Payment Plans (Tables)	12 Months Ended
	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Company Stock Based Award Plans	The following table summarizes information about the Company’s stock-based award plans as of June 30, 2020: Outstanding Outstanding Shares Available for 2016 Plan 1,260,524 0 0 RSU Awards 0 339,359 0
Summary Of Stock Option Activity	A summary of stock option activity under the employees share option plan Service Performance Total Stock Service Weighted- (in years) Aggregate Outstanding at June 30, 2019 817,077 319,717 1,136,794 $ 8.83 8.02 $ 24,679,478 Granted 192,133 67,500 259,633 38.16 Exercised (70,282 ) (29,700 ) (99,982 ) 6.37 Expired (9,270 ) — (9,270 ) 29.45 Forfeited (25,305 ) (1,346 ) (26,651 ) 18.14 Outstanding at June 30, 2020 904,353 356,171 1,260,524 14.72 8.42 22,185,034 Exercisable at June 30, 2020 279,776 221,923 501,699 $ 10.25 8.10 $ 10,520,968
Summary Of Grant-date Fair Value Of Stock Option	Included in the following table is a summary of the grant-date fair value of stock options granted and the related assumptions used in the Binomial models for stock options granted in fiscal 2020, 2019, and 2018. Year Ended June 30, 2020 2019 2018 Expected volatility 75% - 90% 90% 90% Weighted-average volatility 88% 90% 90% Expected dividends 0% 0% 0% Expected term (in years) 10.0 10.0 1.5 - 10.0 Risk-free interest rate 0.68% - 2.65% 1.50% - 2.65% 1.50%
Non Option Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Stock Option Activity	A summary of the status of the Company’s unvested shares as of June 30, 2020, and changes during the year ended June 30, 2020, is presented below: Unvested Shares Service Performance Total Weighted Unvested RSUs outstanding at June 30, 2019 166,667 333,333 500,000 $ 4.48 Granted 146,521 298,022 444,543 39.12 Vested (218,175 ) (387,009 ) (605,184 ) 15.22 Forfeited — — — — Unvested RSUs outstanding at June 30, 2020 95,013 244,346 339,359 $ 30.70

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Geographic Sources of Income (Loss) From Continuing Operations	Geographic sources of income (loss) from continuing operations before income taxes are as follows: Year Ended Year Ended Year Ended (amounts in thousands) June 30, June 30, June 30, United States $ (20,793 ) $ (19,899 ) $ (5,382 ) Foreign (21,233 ) (5,324 ) (8,427 ) Income (loss) from continuing operations before income taxes $ (42,026 ) $ (25,223 ) $ (13,809 )
Summary Of Income Tax Benefit (Expense)	The income tax benefit (expense) as shown in the accompanying consolidated statements of operations includes the following: Year Ended Year Ended Year Ended (amounts in thousands) June 30, June 30, June 30, Current: Federal $ — $ — $ — State 4 — — Foreign — (121 ) (1,074 ) 4 (121 ) (1,074 ) Deferred: Federal — — — State — — — Foreign — — — — — — Total Income Tax Expense (Benefit) $ 4 $ (121 ) $ (1,074 )
Summary Of Provision For Income Taxes	The provision for income taxes differs from the tax computed using the statutory United States federal income tax rate of 21%, 21% and 28% for June 30, 2020, 2019 and 2018 as a result of the following items: (amounts in thousands) Year Ended Year Ended Year Ended Tax expense (benefit) at U.S. statutory rate $ (8,827 ) $ (5,297 ) $ (3,805 ) State income taxes 4 — — Foreign rate differential (1,389 ) (299 ) 120 Tax Credits — (121 ) (1,074 ) Share-based compensation (3,794 ) 535 391 Permanent differences 669 84 796 Change in tax rate — — 2,824 Net change in valuation allowance 13,341 4,977 (326 ) Income tax expense (benefit) $ 4 $ (121 ) $ (1,074 )
Summary Of Deferred Income Tax	A summary of deferred income tax assets is as follows (in thousands): Year Ended June 30, 2020 Year Ended June 30, 2019 Deferred tax liabilities ROU Asset $ (608 ) $ — Total deferred tax liabilities $ (608 ) $ — Deferred tax assets Property, plant and equipment $ 17 $ 7 Accrued expenses 564 15 Intangible assets 255 563 Stock based compensation 2,996 — Lease liability 634 — Net operating loss carryforward 37,756 25,358 Other 285 1 Total deferred tax assets $ 42,507 $ 25,944 Less valuation allowance (41,899 ) (25,944 ) Net deferred tax assets $ 608 $ — Net deferred tax assets / (liabilities) $ — $ —

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Summary Of Reconciliation Of The Basic And Diluted Loss Per Share	The following is a reconciliation of the basic and diluted loss per share computations: Year Ended June 30, 2020 2019 2018 (in thousands) Net Loss $ 42,030 $ 25,102 $ 12,735 Weighted-average common shares—outstanding, basic 20,291 16,065 9,327 Weighted-average common shares—outstanding, diluted 20,291 16,065 9,327 Net loss per common share, basic $ 2.07 $ 1.56 $ 1.37 Net loss per common share, diluted $ 2.07 $ 1.56 $ 1.37

Deed of Cross Guarantee (Tables

Deed of Cross Guarantee (Tables)	12 Months Ended
	Jun. 30, 2020
Guarantees [Abstract]
Consolidated Income Statement Of The Parties To The Deed	Consolidated financial information of parties to the Deed The financial statements below are additional disclosure items specifically required by ASIC and represent the consolidated financial statements of the entities that are party to the Deed only (being the ‘closed group’ and also the ‘extended closed group’ under the Deed). (in thousands) Year Ended June 30, Revenues $ 292 Cost of sales 335 Gross profit (43 ) Operating Expenses: Sales and marketing expenses 488 General and administrative expenses 5,013 Research and development expenses 103 Share-based compensation 16,486 Total operating expenses 22,090 Operating loss (22,133 ) Interest expense 20 Other income 2 Loss before income taxes (22,151 ) Income tax benefit (expense) — Net loss $ (22,151 )
Consolidated Balance Sheet Of The Parties To The Deed	June 30, ASSETS Cash $ 403 Accounts receivable, net 17 R&D tax credits — Prepaids and other current assets 414 Inventory 23 Total current assets 857 Plant and equipment, net 1 Intangibles 364 Total assets $ 1,222 LIABILITIES AND STOCKHOLDERS’ EQUITY Accounts payable and accrued liabilities $ 1,946 Accrued wages and fringe benefits 70 Other current liabilities — Total liabilities $ 2,016 Contributed Equity 232,747 Reserves 31,345 Accumulated deficit (264,886 ) Total stockholders’ equity (deficit) (794 ) Total liabilities and stockholders’ equity (deficit) $ 1,222

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Disclosure Detail Of Quarterly Financial Information	(in thousands, except per share data) Year Ended June 30, September 30, December 31, March 31, June 30, 2020 Revenues $ 3,250 $ 3,259 $ 3,877 $ 3,877 Cost of sales 619 846 634 874 Gross profit 2,631 2,413 3,243 3,003 BARDA income 2,051 386 1,008 481 Operating Expenses: Sales and marketing expenses 2,962 3,738 4,162 3,951 General and administrative expenses 3,071 4,558 4,145 6,361 Research and development expenses 1,635 2,192 2,302 2,332 Share-based compensation 672 2,903 9,048 3,863 Total operating expenses 8,340 13,391 19,657 16,507 Operating loss (3,658 ) (10,592 ) (15,406 ) (13,023 ) Interest expense 11 9 5 8 Other income/(expense) 103 99 363 121 Loss before income taxes (3,566 ) (10,502 ) (15,048 ) (12,910 ) Income tax benefit (expense) — — — (4 ) Net loss $ (3,566 ) $ (10,502 ) $ (15,048 ) $ (12,914 ) Net loss per common share: Basic $ (0.19 ) $ (0.53 ) $ (0.71 ) $ (0.60 ) Diluted $ (0.19 ) $ (0.53 ) $ (0.71 ) $ (0.60 ) Weighted-average common shares: Basic 18,719,857 19,877,676 21,215,246 21,372,892 Diluted 18,719,857 19,877,676 21,215,246 21,372,892 (in thousands, except per share data) Year Ended June 30, September 30, December 31, March 31, June 30, 2019 Revenues $ 269 $ 1,040 $ 1,710 $ 2,455 Cost of sales 232 242 292 505 Gross profit 37 798 1,418 1,950 BARDA income 1,862 1,753 1,238 1,068 Operating Expenses: Sales and marketing expenses 2,163 2,840 3,309 3,941 General and administrative expenses 2,605 3,399 3,650 3,927 Research and development expenses 1,972 2,019 1,809 2,072 Share-based compensation 217 593 567 569 Total operating expenses 6,957 8,851 9,335 10,509 Operating loss (5,058 ) (6,300 ) (6,679 ) (7,491 ) Interest expense 6 5 5 11 Other income/(expense) 37 $ 39 $ 502 $ (246 ) Loss before income taxes (5,027 ) (6,266 ) (6,182 ) (7,748 ) Income tax benefit (expense) (7 ) — — 128 Net loss $ (5,034 ) $ (6,266 ) $ (6,182 ) $ (7,620 ) Net loss per common share: Basic $ (0.38 ) $ (0.44 ) $ (0.34 ) $ (0.41 ) Diluted $ (0.38 ) $ (0.44 ) $ (0.34 ) $ (0.41 ) Weighted-average common shares: Basic 13,240,087 14,165,200 18,263,535 18,665,604 Diluted 13,240,087 14,165,200 18,263,535 18,665,604

The Company - Additional Inform

The Company - Additional Information (Detail)	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of stock exchange ratio	This exchange was conducted on the basis of one share of common stock of AVITA Therapeutics for every 100 ordinary shares of AVITA Medical, effecting an ‘implicit consolidation’ or ‘reverse split’. The holders of ordinary shares of AVITA Medical received one CDI for every 20 ordinary shares held in AVITA Medical, and the holders of AVITA Medical ADSs (each of which represented 20 ordinary shares in AVITA Medical) received one share of common stock in AVITA Therapeutics for every five ADSs held.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash in foreign institutions	$ 476,000	$ 466,000	$ 476,000
Concentration risk, customer	1	0
Restricted cash	$ 200,000	$ 201,000	200,000	$ 0
Allowance for doubtful accounts	18,000	18,000	18,000	17,000	$ 68,000
Capitalized patent costs	$ 225,000	483,000	225,000
Impairments of long-lived assets		$ 0	$ 0	$ 0
Maximum
Estimated useful lives of intangible assets		20 years
Minimum
Estimated useful lives of intangible assets		3 years
Revenue Benchmark
Concentration risk, customer			one	four
Concentration risk, percentage		10.00%	10.50%	10.00%
Revenue Benchmark | Customer One [Member]
Concentration risk, percentage				17.00%
Revenue Benchmark | Customer Two [Member]
Concentration risk, percentage				14.50%
Revenue Benchmark | Customer Three [Member]
Concentration risk, percentage				12.80%
Revenue Benchmark | Customer Four [Member]
Concentration risk, percentage				10.40%
Accounts Receivable
Concentration risk, customer			three
Concentration risk, percentage		10.00%	10.00%
Accounts Receivable | Customer One [Member]
Concentration risk, percentage			14.60%
Accounts Receivable | Customer Two [Member]
Concentration risk, percentage			10.30%
Accounts Receivable | Customer Three [Member]
Concentration risk, percentage			10.10%
Property, Plant and Equipment | Maximum
Estimated useful lives of property plant and equipment		7 years
Property, Plant and Equipment | Minimum
Estimated useful lives of property plant and equipment		3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Allowance for Doubtful Account (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Accounts Receivable Allowance For Credit Loss [Line Items]
Allowance for doubtful accounts at beginning of the year	$ 18	$ 17	$ 68
Bad debt expense	43	6	15
Deductions	(43)	(5)	(66)
Allowance for doubtful accounts at end of the year	$ 18	$ 18	$ 17

Accounting Standards Update - A

Accounting Standards Update - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jul. 01, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Operating lease assets	$ 2,347	$ 2,800
Operating lease liability	2,450	$ 2,900
Restricted cash	201		200	$ 0
Allowance for doubtful accounts	$ 18		$ 18	$ 17	$ 68

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	Jun. 30, 2020	Jul. 01, 2019	Jun. 30, 2019
Leases [Line Items]
Operating lease assets	$ 2,347,000	$ 2,800,000
Operating lease liability	2,450,000	2,900,000
Finance lease liability	$ 11,000	$ 53,000
Minimum
Leases [Line Items]
Remaining lease terms		1 year
Maximum
Leases [Line Items]
Remaining lease terms		5 years

Leases - Summary Of Lease Cost

Leases - Summary Of Lease Cost (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2020USD ($)
Lease Cost [Line Items]
Operating lease cost	$ 701
Variable lease cost	47
Total lease cost	$ 748

Leases - Summary Of Supplementa

Leases - Summary Of Supplemental Cash Flow Information Related To Operating Leases (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2020USD ($)
Disclosure Of Supplemental cash flow information related to operating leases [Line Items]
Operating cash outflows due to operating leases	$ 675
Operating leases

Leases - Summary Of Supplemen_2

Leases - Summary Of Supplemental Balance Sheet Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jul. 01, 2019	Jun. 30, 2019
Disclosure Of Supplemental Balance Sheet Information Related To Operating Leases [Line Items]
Operating lease right-of-use assets	$ 2,347	$ 2,800
Total right-of-use assets	2,347
Operating lease liability, short-term	533
Operating lease liabiltiies, long term	1,917
Total operating lease liabilities	$ 2,450	$ 2,900
Operating lease weighted average remaining lease term (years)	3 years 10 months 27 days
Operating lease weighted average discount rate	7.50%

Leases - Summary Of Maturities

Leases - Summary Of Maturities Of The Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jul. 01, 2019
Lessee Operating Lease Liability Maturity [Line Items]
2021	$ 695
2022	717
2023	740
2024	588
2025	87
Total lease payments	2,827
Less imputed interest	377
Total operating lease liabilities	$ 2,450	$ 2,900

Leases - Summary Of Future Mini

Leases - Summary Of Future Minimum Lease Payments Under Non-Cancellable Leases (Detail) $ in Thousands	Jun. 30, 2020USD ($)
Schedule Of Future Minimum Rental Payments For Operating Leases [Line Items]
2021	$ 530
2022	77
Total operating lease liabilities	$ 607

Inventory - Summary Of Composit

Inventory - Summary Of Composition Of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Inventory [Line Items]
Raw materials and components	$ 947	$ 638
Finished goods	178	104
Total inventory	$ 1,125	$ 742

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory impairments	$ 306,000	$ 36,000	$ 0

Intangible Assets - Summary Of

Intangible Assets - Summary Of Composition Of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 23
Intangible Assets, Gross (Excluding Goodwill)	483	$ 225
Finite Lived Intangible Assets, Accumulated Amortization	(119)
Finite Lived Intangible Assets, Net Carrying Amount	341
Intangible Assets, Net (Excluding Goodwill)	364	225
Trademarks
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 23
Patent 1
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
Finite Lived Intangible Assets, Gross Amount	$ 235	151
Finite Lived Intangible Assets, Accumulated Amortization	(101)
Finite Lived Intangible Assets, Net Carrying Amount	$ 134	151
Patent 2
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite Lived Intangible Assets, Gross Amount	$ 74	22
Finite Lived Intangible Assets, Accumulated Amortization	(9)
Finite Lived Intangible Assets, Net Carrying Amount	$ 65	22
Patent 3
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Finite Lived Intangible Assets, Gross Amount	$ 125	52
Finite Lived Intangible Assets, Accumulated Amortization	(9)
Finite Lived Intangible Assets, Net Carrying Amount	$ 116	$ 52
Patent 5
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 26
Finite Lived Intangible Assets, Net Carrying Amount	$ 26

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of intangible assets	$ 0	$ 0	$ 0
Amortization of intangible assets	$ 119,000	$ 0	$ 0

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization of Amortizable Intangible assets held (Detail) $ in Thousands	Jun. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 100
2022	70
2023	16
2024	15
2025	15
2026 and thereafter	125
Total	$ 341

Property, Plant and Equipment -

Property, Plant and Equipment - Summary Of Composition Of Property, Plant And Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Line Items]
Less: accumulated amortization and depreciation	$ (881)	$ (667)
Total property, plant and equipment, net	1,363	1,309
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 802	462
Computer Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 369	219
Construction In Progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 138	470
Furniture And Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 425	399
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 194	143
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Useful Lives	Lesser of life or lease term
Property, Plant and Equipment, Gross	$ 216	155
RECELL Moulds
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 100	$ 128

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 346,000	$ 269,000	$ 110,000

Prepaids and Other Current As_3

Prepaids and Other Current Assets - Schedule Of Prepaids And Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Prepaid expenses	$ 792	$ 933
Lease deposits	123	40
Other receivables	75	125
Total prepaids and other current assets	$ 990	$ 1,098

Reporting Segment and Geograp_3

Reporting Segment and Geographic Information - Schedule Of Revenue By Region (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Revenue :
Revenues	$ 3,877	$ 3,877	$ 3,259	$ 3,250	$ 2,455	$ 1,710	$ 1,040	$ 269	$ 14,263	$ 5,474	$ 929
United States
Revenue :
Revenues									13,800	4,404
Foreign | Australia
Revenue :
Revenues									292	806	550
Foreign | United Kingdom
Revenue :
Revenues									$ 171	$ 264	$ 379

Contingencies - Additional Info

Contingencies - Additional Information (Detail)	Jun. 30, 2020USD ($)
Threatened Litigation
Litigation liability	$ 0

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) $ / shares in Units, $ in Millions	Jun. 29, 2020	Jun. 30, 2019$ / sharesshares	Jan. 18, 2019USD ($)$ / sharesshares	Jan. 10, 2019USD ($)$ / sharesshares	Dec. 10, 2018USD ($)$ / sharesshares	Jul. 27, 2018USD ($)$ / shares	Jun. 13, 2018USD ($)$ / sharesshares	Nov. 02, 2017USD ($)shares	Oct. 17, 2017USD ($)$ / sharesshares	Dec. 31, 2017shares	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Oct. 31, 2017USD ($)
Class of Stock [Line Items]
Common stock shares authorized		200,000,000									200,000,000
Common stock par value | $ / shares		$ 0.0001									$ 0.0001
Common stock shares issued		18,712,996									21,467,912
Common stock shares outstanding		18,712,996									21,467,912
Preferred stock shares authorized		10,000,000									10,000,000
Preferred stock par value | $ / shares		$ 0.0001									$ 0.0001
Preferred stock shares outstanding		0									0
Sale of stock issue price per share | $ / shares						$ 3.70
Capital to be raised through private placement | $												$ 28.8
Director Share Plan
Class of Stock [Line Items]
Stock shares issued in consideration of services										6,970	15,853
Private Placement
Class of Stock [Line Items]
Proceeds from private placement | $								$ 9.6			$ 81.7
Common stock shares issued during the period								2,765,029			2,033,898
Sale of stock issue price per share | $ / shares											$ 40.17
Sale of stock consideration received on transaction | $											$ 76.6
Capital to be raised through private placement | $													$ 12.1	$ 13.2
Private Placement | Tranche One, June 2018
Class of Stock [Line Items]
Proceeds from private placement | $						$ 2.4
Common stock shares issued during the period		650,000
Private Placement | Tranche One, December 2018
Class of Stock [Line Items]
Proceeds from private placement | $			$ 10.9		$ 17.9
Common stock shares issued during the period			1,899,530		3,100,471
Sale of stock issue price per share | $ / shares			$ 5.76		$ 5.76
Private Placement | Avita Share Purchase Plan
Class of Stock [Line Items]
Proceeds from private placement | $				$ 1.3
Common stock shares issued during the period				220,612
Sale of stock issue price per share | $ / shares				$ 5.74
Private Placement | Tranche One, October 2017
Class of Stock [Line Items]
Proceeds from private placement | $									$ 3.6
Common stock shares issued during the period									1,009,830
Sale of stock issue price per share | $ / shares									$ 3.53
Private Placement | Tranche One, June 2018 Placement
Class of Stock [Line Items]
Proceeds from private placement | $						$ 2.4	$ 9.7
Common stock shares issued during the period							2,554,756
Sale of stock issue price per share | $ / shares							$ 3.79
Shareholders Of Avita Medical
Class of Stock [Line Items]
Reverse stock split ratio	0.01
CDI | Shareholders Of Avita Medical
Class of Stock [Line Items]
Reverse stock split ratio	0.05
Common Stock | Shareholders Of Avita Medical | ADRS
Class of Stock [Line Items]
Reverse stock split ratio	0.05

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Revenue, Performance Obligation [Abstract]
Contract with customer assets	$ 0	$ 0
Contract with customers non current liability	435,000	429,000
Performance obligation estimated revenue expected to be recognised	$ 435,000	$ 429,000

Share-Based Payment Plans - Add

Share-Based Payment Plans - Additional Information (Detail)

Nov. 30, 2017shares

Jun. 01, 2017

Jun. 30, 2020USD ($)shares

Nov. 30, 2019shares

Jun. 30, 2020USD ($)shares

Mar. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Sep. 30, 2019USD ($)

Jun. 30, 2019USD ($)shares

Mar. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2020USD ($)$ / sharesshares

Jun. 30, 2019USD ($)$ / sharesshares

Jun. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation expense

$ 3,863,000

$ 9,048,000

$ 2,903,000

$ 672,000

$ 569,000

$ 567,000

$ 593,000

$ 217,000

$ 16,486,000

$ 1,946,000

$ 1,423,000

Proceeds from exercise of stock options

474,000

$ 252,000

Unrecognised share based compensation compensation expense relating to stock options

$ 4,700,000

4,700,000

4,700,000

Unrecognised share based compensation compensation expense relating to stock options in respect of nonvested awards determined not to be probable.

$ 1,900,000

$ 1,900,000

$ 1,900,000

Unrecognised share based compensation compensation expense relating to stock options weighted average period of recognition

8 months 8 days

Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period | shares

444,543

Share based compensation by share based payment arrangement other than option weighted average grant date fair value | $ / shares

$ 39.12

Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of outstading share capital authorised for issuance share based plan

7.50%

Share based compensation by share based payment arrangement number of shares authorised for issuance | shares

1,610,093

1,610,093

1,403,475

1,610,093

1,403,475

958,034

Share based compensation by share based payment arrangement contractual term of awards

10 years

Share based compensation by share based payment arrangement vesting period

4 years

Share based compensation by share based payment arrangement weighted average grant date of fair value of options granted | $ / shares

$ 26.56

$ 6.67

$ 5.11

Share based compensation by share based payment arrangement intrinsic value of options exercised

$ 3,100,000

$ 1,700,000

$ 0

Proceeds from exercise of stock options

474,000

252,000

0

Unrecognised share based compensation compensation expense relating to stock options

$ 5,800,000

$ 5,800,000

$ 5,800,000

Unrecognised share based compensation compensation expense relating to stock options weighted average period of recognition

1 year 4 months 27 days

Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen | Vesting Period One

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement vesting percentage

25.00%

Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen | Vesting Period Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement vesting percentage

25.00%

Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen | Vesting Period Three

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement vesting percentage

25.00%

Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen | Vesting Period Four

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement vesting percentage

25.00%

Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognised share based compensation compensation expense relating to stock options

$ 6,600,000

$ 6,600,000

$ 6,600,000

Share based compensation by share based payment arrangement other than options total fair value of shares vested

$ 9,200,000

$ 0

$ 0

Share based compensation by share based payment arrangement other than option weighted average grant date fair value | $ / shares

$ 39.12

$ 0

$ 4.48

Restricted Stock Units (RSUs) | Other Executives

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period | shares

49,000

Restricted Stock Units (RSUs) | Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement contractual term of awards

10 years

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period | shares

500,000

395,542

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Service Based Milestone

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arrangement vesting period

3 years

3 years

Share based compensation by share based payment arragement non vested restricted stock units expected to vest | shares

142,520

142,520

142,520

166,667

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Share Price Milestone

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arragement non vested restricted stock units expected to vest | shares

166,667

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Share Price Milestone | Share-based Payment Arrangement, Tranche One

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price multiple for the restricted stock units to vest

2

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Share Price Milestone | Share-based Payment Arrangement, Tranche Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price multiple for the restricted stock units to vest

3

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Share Price Milestone | Share-based Payment Arrangement, Tranche Three

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share price multiple for the restricted stock units to vest

4

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Fulfilling Regulatory Approval

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arragement non vested restricted stock units expected to vest | shares

166,666

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Fulfilling Regulatory Approval | Share-based Payment Arrangement, Tranche One

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

FDA PMA approval of RECELL for burns

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Fulfilling Regulatory Approval | Share-based Payment Arrangement, Tranche Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

Initial BARDA procurement under CLIN 2 of the BARDA Grant

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation by share based payment arragement non vested restricted stock units expected to vest | shares

253,033

253,033

253,033

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval | Share-based Payment Arrangement, Tranche One

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

First patient visit for treatment in an FDA approved U.S. soft tissue and trauma trial by the Company prior to March 3, 2020.

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval | Share-based Payment Arrangement, Tranche Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

First patient visit for treatment in an FDA approved U.S pediatric trial by the Company prior to June 30, 2020

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval | Share-based Payment Arrangement, Tranche Three

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

First patient visit for treatment in an FDA approved U.S pilot vitiligo trial by the Company prior to September 30, 2020.

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval | Share-based Payment Arrangement, Tranche Four

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

FDA application submission for approval of the next generation RECELL device prior to June 30, 2021.

Restricted Stock Units (RSUs) | Long Term Incentive Plan | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval | Share-based Payment Arrangement, Tranche Five

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Description of the milestone to be achieved for vesting of restricted stock awards

FDA approval of the next generation RECELL device prior to June 30, 2022.

Share-Based Payment Plans - Sum

Share-Based Payment Plans - Summary Of Company Stock Based Award Plans (Detail) - shares	Jun. 30, 2020	Jun. 30, 2019
Schedule Of Company Stock Based Award Plans [Line Items]
Outstanding Options	1,260,524	1,136,794
Employee Stock Option | 2016
Schedule Of Company Stock Based Award Plans [Line Items]
Outstanding Options	1,260,524
Outstanding Restricted Stock Units	0
Shares Available for Future Issuance	0
Restricted Stock
Schedule Of Company Stock Based Award Plans [Line Items]
Outstanding Options	0
Outstanding Restricted Stock Units	339,359
Shares Available for Future Issuance	0

Share-Based Payment Plans - S_2

Share-Based Payment Plans - Summary Of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	1,136,794
Granted	259,633
Exercised	(99,982)
Expired	(9,270)
Forfeited	(26,651)
Ending balance	1,260,524	1,136,794
Exercisable	501,699
Weighted average contractual term	8 years 5 months 1 day	8 years 7 days
Weighted average contractual term in exercisable	8 years 1 month 6 days
Aggregate intrinsic value	$ 22,185,034	$ 24,679,478
Aggregate intrinsic value of exercisable	$ 10,520,968
Service Only Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	817,077
Granted	192,133
Exercised	(70,282)
Expired	(9,270)
Forfeited	(25,305)
Ending balance	904,353	817,077
Exercisable	279,776
Weighted Average exercise price beginning balance	$ 8.83
Weighted Average exercise price granted	38.16
Weighted Average exercise price exercised	6.37
Weighted Average exercise price expired	29.45
Weighted Average exercise price forfeited	18.14
Weighted Average exercise price ending balance	14.72	$ 8.83
Weighted Average exercise price exercisable	$ 10.25
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	319,717
Granted	67,500
Exercised	(29,700)
Expired	0
Forfeited	(1,346)
Ending balance	356,171	319,717
Exercisable	221,923

Share-Based Payment Plans - S_3

Share-Based Payment Plans - Summary Of Grant-Date Fair Value Of Stock Option (Detail)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected volatility minimum	75.00%
Expected volatility maximum	90.00%
Expected volatility		90.00%	90.00%
Weighted-average volatility	88.00%	90.00%	90.00%
Expected dividends	0.00%	0.00%	0.00%
Expected term	10 years	10 years
Risk-free interest rate minimum	0.68%	1.50%
Risk-free interest rate maximum	2.65%	2.65%
Risk-free interest rate			1.50%
Minimum
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term			1 year 6 months
Maximum
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term			10 years

Share-Based Payment Plans - S_4

Share-Based Payment Plans - Summary Of Company Unvested Shares (Detail)	12 Months Ended
	Jun. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	500,000
Unvested shares granted	444,543
Unvested shares vested	(605,184)
Unvested shares forfeited	0
Unvested shares ending balance	339,359
Weighted average grant date fair value per unit beginning balance | $ / shares	$ 4.48
Weighted average grant date fair value per unit granted | $ / shares	39.12
Weighted average grant date fair value per unit vested | $ / shares	15.22
Weighted average grant date fair value per unit forfeited | $ / shares	0
Weighted average grant date fair value per unit ending balance | $ / shares	$ 30.70
Non Options Service Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	166,667
Unvested shares granted	146,521
Unvested shares vested	(218,175)
Unvested shares forfeited	0
Unvested shares ending balance	95,013
Non Option Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	333,333
Unvested shares granted	298,022
Unvested shares vested	(387,009)
Unvested shares forfeited	0
Unvested shares ending balance	244,346

Income Taxes - Geographic Sourc

Income Taxes - Geographic Sources of Income (Loss) From Continuing Operations (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
United States									$ (20,793)	$ (19,899)	$ (5,382)
Foreign									(21,233)	(5,324)	(8,427)
Income (loss) from continuing operations before income taxes	$ (12,910)	$ (15,048)	$ (10,502)	$ (3,566)	$ (7,748)	$ (6,182)	$ (6,266)	$ (5,027)	$ (42,026)	$ (25,223)	$ (13,809)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Benefit (Expense) (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Current:
State				$ 4
Foreign					$ (121)	$ (1,074)
Current Foreign Tax Expense (Benefit)				4	(121)	(1,074)
Income tax expense (benefit)	$ 4	$ (128)	$ 7	$ 4	$ (121)	$ (1,074)

Income Taxes - Summary of Provi

Income Taxes - Summary of Provision For Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Tax expense (benefit) at U.S. statutory rate				$ (8,827)	$ (5,297)	$ (3,805)
State income taxes				4
Foreign rate differential				(1,389)	(299)	120
Tax Credits					(121)	(1,074)
Share-based compensation				(3,794)	535	391
Permanent differences				669	84	796
Change in tax rate						2,824
Net change in valuation allowance				13,341	4,977	(326)
Income tax expense (benefit)	$ 4	$ (128)	$ 7	$ 4	$ (121)	$ (1,074)

Income Taxes - Summary of Pro_2

Income Taxes - Summary of Provision For Income Taxes (Parenthetical) (Detail)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	21.00%	28.00%	21.00%

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Income Tax (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Deferred tax liabilities
ROU Asset	$ (608)
Total deferred tax liabilities	(608)
Deferred tax assets
Property, plant and equipment	17	$ 7
Accrued expenses	564	15
Intangible assets	255	563
Stock based compensation	2,996
Lease liability	634
Net operating loss carryforward	37,756	25,358
Other	285	1
Total deferred tax assets	42,507	25,944
Less valuation allowance	(41,899)	$ (25,944)
Net deferred tax assets	608
Net deferred tax assets / (liabilities)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Line Items]
Deferred tax assets valuation allowance	$ 41,899,000	$ 25,944,000
Unrecognised income tax benenfits	$ 0	$ 0
Federal statutory income tax rate	21.00%	21.00%	28.00%	21.00%
Tax Cut And Jobs Act
Income Tax Disclosure [Line Items]
Percentage of tax amount likely to be realised	50.00%	50.00%	50.00%
Tax Year 2038
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 21,700,000
Internal Revenue Service (IRS)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	88,500,000
State and Local Jurisdiction
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	57,500,000
Her Majesty's Revenue and Customs (HMRC)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	29,800,000
Australian Taxation Office
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 34,100,000

Loss per Share - Summary of Rec

Loss per Share - Summary of Reconciliation of The Basic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net loss	$ (12,914)	$ (15,048)	$ (10,502)	$ (3,566)	$ (7,620)	$ (6,182)	$ (6,266)	$ (5,034)	$ (42,030)	$ (25,102)	$ (12,735)
Weighted-average common shares—outstanding, basic	21,372,892	21,215,246	19,877,676	18,719,857	18,665,604	18,263,535	14,165,200	13,240,087	20,290,966	16,064,588	9,326,810
Weighted-average common shares—outstanding, diluted	21,372,892	21,215,246	19,877,676	18,719,857	18,665,604	18,263,535	14,165,200	13,240,087	20,290,966	16,064,588	9,326,810
Net loss per common share, basic	$ (0.60)	$ (0.71)	$ (0.53)	$ (0.19)	$ (0.41)	$ (0.34)	$ (0.44)	$ (0.38)	$ 2.07	$ 1.56	$ 1.37
Net loss per common share, diluted	$ (0.60)	$ (0.71)	$ (0.53)	$ (0.19)	$ (0.41)	$ (0.34)	$ (0.44)	$ (0.38)	$ 2.07	$ 1.56	$ 1.37

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Retirement Benefits [Abstract]
Defined contribution plan employers matching contribution percentage of employees pay	6.00%
Employers contribution to retirement plan	$ 713,000	$ 594,000	$ 290,000

Deed of Cross Guarantee - Conso

Deed of Cross Guarantee - Consolidated Income Statement Of The Parties To The Deed (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Consolidated income statement of the parties to the deed [Line Items]
Revenues	$ 3,877	$ 3,877	$ 3,259	$ 3,250	$ 2,455	$ 1,710	$ 1,040	$ 269	$ 14,263	$ 5,474	$ 929
Cost of sales	874	634	846	619	505	292	242	232	2,973	1,271	546
Gross profit	3,003	3,243	2,413	2,631	1,950	1,418	798	37	11,290	4,203	383
Operating Expenses:
Sales and marketing expenses	3,951	4,162	3,738	2,962	3,941	3,309	2,840	2,163	14,813	12,253	4,875
General and administrative expenses	6,361	4,145	4,558	3,071	3,927	3,650	3,399	2,605	18,135	13,581	9,403
Research and development expenses	2,332	2,302	2,192	1,635	2,072	1,809	2,019	1,972	8,461	7,872	6,257
Share-based compensation	3,863	9,048	2,903	672	569	567	593	217	16,486	1,946	1,423
Total operating expenses	16,507	19,657	13,391	8,340	10,509	9,335	8,851	6,957	57,895	35,652	21,958
Operating loss	(13,023)	(15,406)	(10,592)	(3,658)	(7,491)	(6,679)	(6,300)	(5,058)	(42,679)	(25,528)	(13,841)
Interest expense	8	5	9	11	11	5	5	6	33	27	21
Other income	121	363	99	103	(246)	502	39	37
Loss before income taxes	(12,910)	(15,048)	(10,502)	(3,566)	(7,748)	(6,182)	(6,266)	(5,027)	(42,026)	(25,223)	(13,809)
Net loss	$ (12,914)	$ (15,048)	$ (10,502)	$ (3,566)	$ (7,620)	$ (6,182)	$ (6,266)	$ (5,034)	(42,030)	$ (25,102)	$ (12,735)
Avita Medical And Australian Wholly Owned Subsidaries Closed Group
Consolidated income statement of the parties to the deed [Line Items]
Revenues									292
Cost of sales									335
Gross profit									(43)
Operating Expenses:
Sales and marketing expenses									488
General and administrative expenses									5,013
Research and development expenses									103
Share-based compensation									16,486
Total operating expenses									22,090
Operating loss									(22,133)
Interest expense									20
Other income									2
Loss before income taxes									(22,151)
Net loss									$ (22,151)

Deed of Cross Guarantee - Con_2

Deed of Cross Guarantee - Consolidated Balance Sheet Of The Parties To The Deed (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
CURRENT ASSETS
Cash	$ 73,639	$ 20,174
Accounts receivable, net	2,076	1,403
Prepaids and other current assets	990	1,098
Inventory	1,125	742
Total current assets	78,387	24,125
Plant and equipment, net	1,363	1,309
Intangibles	364	225
Total assets	82,462	25,784
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	4,333	1,916
Accrued wages and fringe benefits	2,816	2,127
Total liabilities	10,061	4,952
Shareholders' Equity:
Accumulated deficit	(194,913)	(152,828)
Total stockholders' equity (deficit)	72,401	20,832	$ 14,032	$ 3,929
Total liabilities and shareholders' equity	82,462	$ 25,784
Avita Medical And Australian Wholly Owned Subsidaries Closed Group
CURRENT ASSETS
Cash	403
Accounts receivable, net	17
Prepaids and other current assets	414
Inventory	23
Total current assets	857
Plant and equipment, net	1
Intangibles	364
Total assets	1,222
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	1,946
Accrued wages and fringe benefits	70
Total liabilities	2,016
Shareholders' Equity:
Contributed Equity	232,747
Reserves	31,345
Accumulated deficit	(264,886)
Total stockholders' equity (deficit)	(794)
Total liabilities and shareholders' equity	$ 1,222

Quarterly Results (Unaudited) -

Quarterly Results (Unaudited) - Disclosure Detail Of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Quarterly Financial Data [Abstract]
Revenues	$ 3,877	$ 3,877	$ 3,259	$ 3,250	$ 2,455	$ 1,710	$ 1,040	$ 269	$ 14,263	$ 5,474	$ 929
Cost of sales	874	634	846	619	505	292	242	232	2,973	1,271	546
Gross profit	3,003	3,243	2,413	2,631	1,950	1,418	798	37	11,290	4,203	383
BARDA income	481	1,008	386	2,051	1,068	1,238	1,753	1,862	3,926	5,921	7,734
Operating Expenses:
Sales and marketing expenses	3,951	4,162	3,738	2,962	3,941	3,309	2,840	2,163	14,813	12,253	4,875
General and administrative expenses	6,361	4,145	4,558	3,071	3,927	3,650	3,399	2,605	18,135	13,581	9,403
Research and development expenses	2,332	2,302	2,192	1,635	2,072	1,809	2,019	1,972	8,461	7,872	6,257
Share-based compensation	3,863	9,048	2,903	672	569	567	593	217	16,486	1,946	1,423
Total operating expenses	16,507	19,657	13,391	8,340	10,509	9,335	8,851	6,957	57,895	35,652	21,958
Operating loss	(13,023)	(15,406)	(10,592)	(3,658)	(7,491)	(6,679)	(6,300)	(5,058)	(42,679)	(25,528)	(13,841)
Interest expense	8	5	9	11	11	5	5	6	33	27	21
Other income/(expense)	121	363	99	103	(246)	502	39	37
Loss before income taxes	(12,910)	(15,048)	(10,502)	(3,566)	(7,748)	(6,182)	(6,266)	(5,027)	(42,026)	(25,223)	(13,809)
Income tax benefit (expense)	(4)				128			(7)	(4)	121	1,074
Net loss	$ (12,914)	$ (15,048)	$ (10,502)	$ (3,566)	$ (7,620)	$ (6,182)	$ (6,266)	$ (5,034)	$ (42,030)	$ (25,102)	$ (12,735)
Net loss per common share:
Basic	$ (0.60)	$ (0.71)	$ (0.53)	$ (0.19)	$ (0.41)	$ (0.34)	$ (0.44)	$ (0.38)	$ 2.07	$ 1.56	$ 1.37
Diluted	$ (0.60)	$ (0.71)	$ (0.53)	$ (0.19)	$ (0.41)	$ (0.34)	$ (0.44)	$ (0.38)	$ 2.07	$ 1.56	$ 1.37
Weighted-average common shares:
Basic	21,372,892	21,215,246	19,877,676	18,719,857	18,665,604	18,263,535	14,165,200	13,240,087	20,290,966	16,064,588	9,326,810
Diluted	21,372,892	21,215,246	19,877,676	18,719,857	18,665,604	18,263,535	14,165,200	13,240,087	20,290,966	16,064,588	9,326,810